Background It has been hypothesized that incomplete endothelialization and delayed vascular healing may trigger stent thrombosis events after drug-eluting stent (DES) implantation. We aimed to demonstrate non-inferiority in terms of neointimal coverage of novel Cre8 DES at 3 months, compared to Vision/Multilink8 Bare Metal Stent (BMS) at 1 month.
Methods The ranDomizEd coMparisOn betweeN novel Cre8 DES and BMS to assess neoinTimal coveRAge by OCT Evaluation (DEMONSTRATE) was a multicenter, randomized, parallel group study. Thirty-eight patients undergoing angioplasty of de-novo coronary lesion were randomized to Cre8 (19) or Vision/Multilink8 (19) stent placement at 6 OCT-experienced centers. Primary end-point was the Ratio of Uncovered to Total Stent Struts Per Cross Section (RUTTS) score of < 30%, determined by OCT at 3 and 1 months for Cre8 and Vision/Multilink8, respectively. Percentage of uncovered/malapposed stent struts, neointimal growth and thickness were the main secondary end-points.
Results The primary end-point of RUTTS score < 30% occurred in 99.8% (899/901) of Cre8 struts and in 99.6% (1116/1121) of Vision/Multilink8 struts (difference 0.2, CI 95% - 0.2 to 0.6, p for noninferiority < 0.001). The percentage of uncovered/malapposed struts was comparable (0.36 ± 0.64 vs. 0.12 ± 0.24, p = 0.145) in the two study groups, while both neointimal percentage area (8.46 ± 5.29 vs. 19.84 ± 15.93, p < 0.001) and thickness (0.07 ± 0.04 vs. 0.16 ± 0.12, p < 0.001) were significantly reduced by Cre8 stent.
Conclusions The Cre8 DES at 3 months has comparable strut coverage to Vision/Multilink8 BMS at 1 month while preserving a greater efficacy in neo-intima formation reduction. Further studies to assess clinical implication of these Cre8 characteristics are warranted.
- Drug-eluting stent
- Optical coherence tomography
- Randomized controlled trial